NEPHROS INC·4

Dec 15, 4:48 PM ET

Spandow Oliver J. 4

4 · NEPHROS INC · Filed Dec 15, 2023

Insider Transaction Report

Form 4
Period: 2023-12-13
Transactions
  • Award

    Common Stock

    2023-12-13+14,29481,604 total
Holdings
  • Stock Option (Right to Buy)

    Exercise: $8.57Exp: 2029-12-16Common Stock (5,568 underlying)
    5,568
  • Stock Option (Right to Buy)

    Exercise: $6.82Exp: 2031-12-14Common Stock (7,062 underlying)
    7,062
  • Stock Option (Right to Buy)

    Exercise: $1.07Exp: 2032-01-05Common Stock (7,080 underlying)
    7,080
  • Stock Option (Right to Buy)

    Exercise: $5.58Exp: 2028-08-10Common Stock (9,466 underlying)
    9,466
  • Stock Option (Right to Buy)

    Exercise: $5.85Exp: 2028-12-19Common Stock (5,161 underlying)
    5,161
  • Stock Option (Right to Buy)

    Exercise: $8.06Exp: 2031-01-06Common Stock (6,850 underlying)
    6,850
Footnotes (4)
  • [F1]Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.
  • [F2]Fully exercisable.
  • [F3]This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23.
  • [F4]This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES